van der Zande, Hendrik J. P. http://orcid.org/0000-0003-1479-1934
Lambooij, Joost M. http://orcid.org/0000-0002-4853-5843
Chavanelle, Vivien http://orcid.org/0000-0003-0761-3355
Zawistowska-Deniziak, Anna
Otero, Yolanda
Otto, Frank
Lantier, Louise http://orcid.org/0000-0002-6620-4976
McGuinness, Owen P. http://orcid.org/0000-0002-1778-3203
Le Joubioux, Florian
Giera, Martin http://orcid.org/0000-0003-1684-1894
Maugard, Thierry
Peltier, SĂ©bastien L.
Sirvent, Pascal
Guigas, Bruno http://orcid.org/0000-0002-8856-5799
Article History
Received: 14 February 2021
Revised: 5 May 2021
Accepted: 18 May 2021
First Online: 2 June 2021
Compliance with ethical standards
:
: VC, YO, FLJ, SLP, and PS are all employees of Valbiotis. SLP and PS are listed as co-inventors on Totum-63 patent and possess company stock. None of the other authors have any potential competing interests. This work was supported in part by National Institute of Diabetes and Digestive and Kidney Diseases grants DK059637 and S10RR028101 (LL, OMcG), the NWO project 184.034.019 (MG), and Valbiotis (BG). Study design, collection of the data, analysis and interpretation of the results, writing and decision to submit the article for publication was performed by Guigas’ group at the Leiden University Medical Center, in agreement with Valbiotis.